ArticleMolecular pharmacology2021
Novel Human-Derived
Open access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Development and Characterization of a Patient-DerivedJTO clinical and research reports · 2026Article
- Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells.Molecular oncology · 2026Article
- Article
- A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes.Biology open · 2023Article
- Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.International journal of molecular sciences · 2023Review
- A comprehensive overview of the relationship between RET gene and tumor occurrence.Frontiers in oncology · 2023Review
- Research Progress on RET Fusion in Non-Small-Cell Lung Cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Laura SchubertDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Anh T LeDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Adriana Estrada-BernalDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Andrea E DoakDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Minjae YooDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Sarah E FerraraDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Andrew GoodspeedDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Fumi KinoseDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Uwe RixDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Aik-Choon TanDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida.
Robert C DoebeleDepartment of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado (L.S., A.T.L., A.E.-B., A.E.D., M.Y., A.-C.T., R.C.D.); University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado (S.E.F., A.G.); Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado (A.G.); and Department of Thoracic Oncology (F.K.), Department of Drug Discovery (U.R.), and Department of Biostatistics and Bioinformatics (A.-C.T.), Moffitt Cancer Center, Tampa, Florida robert.doebele@cuanschutz.edu.
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USUniversity of Colorado Cancer Center · USMoffitt Cancer Center · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MTissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8MTraining Program in Cancer BiologyT32CA190216 · NCI · UNIVERSITY OF COLORADO DENVER · PI Craig T. Jordan · 2016 to 2026
$3.5MColorado Clinical and Translational Sciences InstituteTL1TR001081 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$1.3MDetermining the role of RET fusion kinases' 5' partner and signaling in response to RET inhibitorsF31CA228320 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHUBERT, LAURA · 2018 to 2019
$45kNCATS NIH HHS TL1 TR001081NCI NIH HHS F31 CA228320NCI NIH HHS P30 CA046934NCI NIH HHS P50 CA058187NCI NIH HHS T32 CA190216
Abstract
Rearranged during transfection (
Indexed as
Signal TransductionAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell CycleCell Line, TumorFemaleHumansLung NeoplasmsMiceMice, NudeProtein Kinase InhibitorsProto-Oncogene Proteins c-retRecombinant Fusion ProteinsXenograft Model Antitumor AssaysAntineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins c-retRecombinant Fusion Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.